Clinical trials: ILD
Covid19, Cytokine Storm
Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients
SARS-CoV-2 infection induces a hyperinflammatory syndrome, causing the acute respiratory distress syndrome, massive lung cell destruction and, as a plausible sequelae, pulmonary fibrosis in COVID-19 patients.
- Conditions
- Covid19, Cytokine Storm, Regulation of Inflammatory Response, Pulmonary Fibrosis
- Trial name
- NCT04517162
- Testing
- Collagen-Polyvinylpyrrolidone
- Where
- Mexico
- Volunteers
- 90 people
- Sponsor
- Janette Furuzawa Carballeda
Chronic Respiratory Failure, Hypoxemia
Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia
The aim of this multicenter crossover trial is to describe the effect of adding a therapeutic dose of exertional oxygen therapy, in terms of exercise performance, gas exchange, heart rate, symptoms perception and subjective…
- Conditions
- Chronic Respiratory Failure, Hypoxemia, Chronic Obstructive Pulmonary Disease (COPD), Interstitial Lung Disease
- Trial name
- NCT07451977
- Testing
- Usual Oxygen During 6-Minute Walk Test, Supplemental Oxygen During 6-Minute Walk Test
- Where
- 6 sites in Italy
- Volunteers
- 114 people
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Langerhans Cell Histiocytosis
Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is a rare, heterogeneous histiocytic disorder occurring most commonly in children. Because of the rarity of LCH in adults and a lack of prospective randomized trials, the treatment strategy for…
- Trial name
- NCT04120519
- Testing
- thalidomide combined with dexamethasone and cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Idiopathic Pulmonary Fibrosis (IPF)
Downhill Walking in IPF
In this study; will examine the effects of downhill walking (eccentric exercise training) on exercise capacity, quality of life, and blood lactate levels in individuals with IPF.
- Trial name
- NCT06756230
- Testing
- Pulmonary Rehabilitation, Downhill Walking, Treadmill Walking without incline
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Saglik Bilimleri Universitesi
Cancer
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
This was a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors.
- Trial name
- NCT02124772
- Testing
- Trametinib, Dabrafenib
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Granulomatous and Lymphocytic Interstitial Lung Disease
Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable Immunodeficiency
This phase II study will assess the effect of a treatment combination of Rituximab and azathioprine in patients with Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) compared to placebo, based on change in lung…
- Trial name
- NCT02789397
- Testing
- Rituximab (RTX) and Azathioprine (AZA)
- Sponsor
- Medical College of Wisconsin
Pulmonary Fibrosis, Breast Cancer
Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients
Two hundred and sixty patients with breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms.
- Trial name
- CONSET (NCT00896155)
- Testing
- Tamoxifen, Radiotherapy
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Tata Memorial Hospital
Interstitial Lung Disease, Pulmonary Hypertension
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
- Trial name
- PHINDER (NCT05776225)
- Testing
- Right heart catheterization (RHC)
- Where
- 42 sites in United States
- Volunteers
- 314 people
- Sponsor
- United Therapeutics
Pulmonary Sarcoidosis
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement
- Trial name
- NCT06169397
- Testing
- XTMAB-16
- Where
- 11 sites in United States, Czechia and 2 more
- Volunteers
- 31 people
- Sponsor
- Xentria, Inc.
Idiopathic Pulmonary Fibrosis
D2212C00002 J-Phase II Study
The purpose of the study is to evaluate the safety and tolerability of multiple-doses of tralokinumab in Japanese patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT02036580
- Testing
- tralokinumab cohort 1, tralokinumab cohort 2
- Where
- 5 sites in Japan
- Volunteers
- 37 people
- Sponsor
- AstraZeneca
Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of…
- Trial name
- NCT04968574
- Testing
- taladegib
- Where
- 24 sites in Australia, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Endeavor Biomedicines, Inc.
Granulomatosis With Polyangiitis, Wegener Granulomatosis
The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach
This is a randomized controlled trial in patients with a diagnosis of granulomatosis with polyangiitis (GPA; Wegener's)that are in remission to evaluate the effects of using low-dose glucocorticoids ( 5 mg/day of prednisone) as…
- Conditions
- Granulomatosis With Polyangiitis, Wegener Granulomatosis, Vasculitis
- Trial name
- TAPIR (NCT01933724)
- Testing
- 5 mg prednisone, 0 mg prednisone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Interstitial Lung Diseases (ILD)
Functional MRI for Monitoring Progression and Assessing Trends in ILD
The main objective of this study is to investigate the utility of functional MRI to differentiate, characterize, and monitor subgroups of ILD.
- Trial name
- IMPACT-ILD (NCT07300696)
- Testing
- Lung MRI Protocol with Functional and Contrast-Enhanced Sequences
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Heidelberg
Healthy Participants
A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
- Trial name
- NCT05684289
- Testing
- BMS-986278, Sildenafil
- Where
- 2 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis, Hypoxemia
Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF
This study is a randomized, double-blind, placebo-controlled trial in which eligible IPF subjects will be randomized to receive GBT440 or Placebo orally daily.
- Trial name
- NCT02846324
- Testing
- GBT440
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Global Blood Therapeutics
Scleroderma, Systemic, Lung Diseases, Interstitial
Functional Exercise Tests in Patients With Systemic Sclerosis
The aim of the study is to examine the validity of peripheral oxygen saturation measurement during the 6-minute walk test in patients with Systemic Sclerosis (SSc) and to examine the utility of two other functional tests as…
- Conditions
- Scleroderma, Systemic, Lung Diseases, Interstitial, Pulmonary Arterial Hypertension, Acroosteolysis
- Trial name
- NCT04650659
- Testing
- 6-minute walk test part one, 6-minute walk test part two, 1-minute sit-to-stand test
- Where
- Denmark
- Volunteers
- 83 people
- Sponsor
- University of Aarhus
COVID-19, Pulmonary Fibrosis
Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands
To date, little is known about the short and long-term complications of COVID-19. In order to obtain more insights in disease course and recovery of COVID-19 and to improve care after hospital admission, patients with COVID-19…
- Trial name
- HOMECOMIN' (NCT04488562)
- Where
- 3 sites in Netherlands
- Volunteers
- 133 people
- Sponsor
- Erasmus Medical Center
Langerhans Cell Histiocytosis
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).
- Trial name
- NCT02205762
- Testing
- Prednisone, Vinblastine, mercaptopurine
- Where
- 42 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- North American Consortium for Histiocytosis
Idiopathic Pulmonary Fibrosis
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018_055 in healthy…
- Trial name
- NCT05154240
- Testing
- INS018_055
- Where
- New Zealand
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- InSilico Medicine Hong Kong Limited
Cystic Fibrosis, Pulmonary Fibrosis
Role of Genetic Factors in the Development of Lung Disease
This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examining the genes in lung cells of patients with lung disease.
- Conditions
- Cystic Fibrosis, Pulmonary Fibrosis, Tuberous Sclerosis, Asthma
- Trial name
- NCT00001532
- Where
- 2 sites in United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)